Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.
Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.
Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.
Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.
John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.
Dennis J. Slamon, MD, PhD, discusses new opportunities for treatment advances in ovarian cancer.
Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.
Olaparib tablets reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.
Ovarian cancer incidence and mortality have declined significantly over the past few decades, but eliminating racial disparities in treatment and improving prevention and early detection could help save even more women.
The FDA has approved bevacizumab for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.